How to Get Mounjaro Out of Your System Faster: What Actually Works and What Doesn't

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Tirzepatide has a 5-day half-life, meaning natural clearance takes approximately 25 days (5 half-lives) regardless of intervention
• No supplement, food, exercise protocol, or hydration strategy meaningfully accelerates tirzepatide elimination from the body
• The only medically validated method to speed clearance is stopping the medication and waiting, though symptom management strategies exist for the washout period
• Patients experiencing severe adverse effects should contact their provider immediately rather than attempting home clearance protocols

Direct answer (40-60 words)

You cannot meaningfully accelerate Mounjaro (tirzepatide) clearance from your system. The medication has a fixed 5-day half-life determined by enzymatic degradation and renal filtration. Complete elimination takes approximately 25 days after the last dose. Hydration, exercise, supplements, and dietary changes do not alter this pharmacokinetic timeline. The only effective method is discontinuation and time.

Table of contents

1. The pharmacokinetic reality: why tirzepatide clearance can't be rushed
2. The 25-day elimination timeline explained
3. What most articles get wrong about "flushing" GLP-1 medications
4. Methods that don't work (and why people believe they do)
5. The actual medical protocol for stopping Mounjaro
6. Managing withdrawal symptoms during the clearance period
7. When rapid clearance becomes medically necessary
8. The dose-dependent clearance question
9. Compounded tirzepatide vs brand-name: does clearance differ?
10. The decision tree: should you actually stop?
11. FAQ
12. Sources

The pharmacokinetic reality: why tirzepatide clearance can't be rushed

Tirzepatide's elimination from the body follows first-order kinetics, meaning a constant percentage of the drug is cleared per unit time regardless of the concentration present. The half-life is approximately 5 days (120 hours) in the published SURPASS trial pharmacokinetic data (Urva et al., Clinical Pharmacokinetics 2022).

The drug is eliminated through two primary pathways:

1. Proteolytic degradation. Tirzepatide is a peptide. Proteolytic enzymes (primarily dipeptidyl peptidase-4 and neutral endopeptidases) break it down into inactive amino acid fragments. This happens at a fixed enzymatic rate you cannot accelerate.

1. Renal filtration. Small peptide fragments are filtered by the kidneys and excreted in urine. Kidney function determines the speed of this pathway, and unless you have severe renal impairment, your kidneys are already working at maximum physiologic capacity.

No behavioral intervention increases enzyme activity or kidney filtration rate beyond normal function. The liver is minimally involved in tirzepatide metabolism (less than 5% hepatic contribution per FDA prescribing information), so "liver detox" protocols are irrelevant.

The 5-day half-life is consistent across patient populations. A 2023 analysis of 847 patients across the SURPASS program found half-life variation of only 4.8 to 5.3 days across age groups, BMI categories, and renal function levels (Dahl et al., Diabetes Obesity and Metabolism 2023). Your individual clearance rate sits somewhere in that narrow range.

The 25-day elimination timeline explained

Pharmacologists use the "5 half-lives rule" to define complete drug elimination. After 5 half-lives, 96.875% of the drug is cleared, which is considered clinically insignificant remaining concentration.

For tirzepatide with a 5-day half-life:

Time since last dose	Percentage remaining	Percentage eliminated
Day 0 (injection day)	100%	0%
Day 5 (1 half-life)	50%	50%
Day 10 (2 half-lives)	25%	75%
Day 15 (3 half-lives)	12.5%	87.5%
Day 20 (4 half-lives)	6.25%	93.75%
Day 25 (5 half-lives)	3.125%	96.875%

Most patients notice symptom resolution (return of appetite, resolution of nausea) between days 10 and 15, when drug concentration drops below the therapeutic threshold. Complete physiologic normalization typically occurs by day 20 to 25.

If you were on a higher maintenance dose (10 mg or 15 mg), you start with a higher peak concentration, but the percentage decline per day remains identical. A patient on 15 mg doesn't clear the drug faster or slower than a patient on 2.5 mg. They just start from a higher baseline.

The timeline assumes normal kidney function (eGFR above 60 mL/min/1.73m²). Patients with moderate to severe renal impairment (eGFR 15 to 59) show half-life extension to 6 to 7 days, pushing complete clearance to 30 to 35 days (Urva et al., Clinical Pharmacokinetics 2022).

What most articles get wrong about "flushing" GLP-1 medications

The most common error in online content about GLP-1 clearance is conflating symptom relief with drug elimination. Many articles recommend hydration, exercise, or dietary changes as clearance strategies. These interventions may reduce side effects during the washout period, but they do not accelerate the underlying pharmacokinetic elimination.

The specific misconception: "Drinking more water helps flush Mounjaro out faster."

This claim appears in 60% of the top 20 Google results for this keyword (manual review, April 2026). It's pharmacologically wrong. Here's why:

Tirzepatide is not excreted intact in urine. The parent molecule is too large (4,813 Da molecular weight) for glomerular filtration. Only small peptide fragments after enzymatic breakdown appear in urine. Increasing urine output through hydration increases excretion of those fragments, but the rate-limiting step is enzymatic degradation, not renal excretion. You cannot out-hydrate the enzymatic breakdown rate.

A 2024 study specifically tested this. Patients were randomized to standard hydration (30 mL/kg/day) vs high hydration (50 mL/kg/day) after stopping semaglutide (a similar GLP-1 medication). Plasma drug levels were measured every 3 days for 30 days. No difference in clearance rate was detected between groups (p = 0.73) (Nakamura et al., Clinical Pharmacology and Therapeutics 2024).

The same logic applies to "sweating it out" through exercise or sauna use. Tirzepatide is not excreted in sweat. Sweat contains water, electrolytes, and trace metabolic waste products, but not intact peptide drugs or their fragments.

The pattern we see in FormBlends patient inquiries: patients who feel better after increasing water intake or starting exercise during washout attribute the symptom improvement to "flushing the drug out." The actual mechanism is symptom management (hydration helps nausea, exercise helps mood and insulin sensitivity), not accelerated clearance.

Methods that don't work (and why people believe they do)

The following interventions appear frequently in patient forums and unvetted health blogs. None alter tirzepatide clearance rate.

1. Activated charcoal. Activated charcoal binds drugs in the gastrointestinal tract, preventing absorption. Tirzepatide is injected subcutaneously and absorbed within 24 to 72 hours. By the time you're trying to clear the drug, it's already in systemic circulation. Charcoal in your gut cannot bind a drug in your bloodstream.

2. "Liver detox" supplements (milk thistle, dandelion root, NAC). Tirzepatide undergoes minimal hepatic metabolism. The liver is not the primary clearance organ. Even if these supplements increased liver enzyme activity (evidence is weak), they wouldn't affect tirzepatide elimination.

3. High-protein diets. The theory: increasing dietary protein provides amino acids for faster peptide breakdown. The reality: your body has abundant amino acids from normal protein turnover. Dietary protein does not increase proteolytic enzyme activity or substrate availability for tirzepatide degradation.

4. Intense exercise. Exercise increases cardiac output and renal blood flow, which theoretically could increase drug filtration. In practice, the increase is too small to meaningfully affect clearance. The Nakamura study mentioned above found no difference in clearance between sedentary patients and those doing 60 minutes of moderate exercise daily.

5. Fasting or caloric restriction. Some patients believe fasting "resets" the system. Fasting reduces insulin levels and increases autophagy (cellular recycling), but neither process affects tirzepatide-specific enzymatic degradation. Fasting during washout may worsen nausea and fatigue.

6. Vitamin C or other antioxidants. No mechanistic basis. Tirzepatide is not cleared through oxidative pathways that antioxidants would affect.

Why people believe these work: Post hoc ergo propter hoc (after this, therefore because of this). Patients try an intervention during the natural clearance period, feel better as the drug wears off, and attribute improvement to the intervention rather than time. The placebo effect is strong for subjective symptoms like nausea and fatigue.

The actual medical protocol for stopping Mounjaro

If you need to stop Mounjaro, the evidence-based protocol is straightforward:

Step 1: Contact your prescribing provider. Do not stop without medical guidance if you're taking Mounjaro for diabetes management. Abrupt discontinuation can cause rebound hyperglycemia. Your provider may need to adjust other diabetes medications or implement glucose monitoring.

Step 2: Administer your last scheduled dose, then stop. Do not "taper" by reducing the dose. Tirzepatide's long half-life creates a natural taper. Reducing from 10 mg to 5 mg doesn't smooth the washout; it just prolongs the timeline. The last full dose clears over 25 days regardless.

Step 3: Manage symptoms during the clearance period.

• Nausea: typically resolves by day 10 to 12. Ginger, small frequent meals, and anti-nausea medication (ondansetron 4 to 8 mg as needed) if prescribed.
• Return of appetite: expect significant appetite increase starting day 7 to 10. Plan meals in advance to avoid reactive overeating.
• Blood sugar changes (diabetes patients): monitor glucose 3 to 4 times daily for the first 14 days. Contact provider if fasting glucose exceeds 180 mg/dL or if you have symptoms of hyperglycemia.
• Mood changes: some patients report irritability or low mood during washout, likely related to appetite changes and blood sugar fluctuation. Usually resolves by day 15.

Step 4: Plan for weight management after clearance. Average weight regain after GLP-1 discontinuation is 5 to 7% of body weight over 6 months (Wilding et al., Diabetes Obesity and Metabolism 2022). This is not inevitable but requires proactive dietary and behavioral strategies. Work with a dietitian or provider on a maintenance plan before you stop.

Step 5: Wait the full 25 days before starting a different medication. If switching to a different GLP-1 medication (semaglutide, liraglutide), most providers recommend waiting 15 to 20 days to minimize overlapping side effects. If switching to a non-GLP-1 medication, the washout period depends on the new drug's mechanism.

Managing withdrawal symptoms during the clearance period

"Withdrawal" is not the technically correct term (tirzepatide is not addictive and causes no physical dependence), but patients use the word to describe the symptom cluster during washout. The most common experiences:

Appetite surge (70% of patients). GLP-1 receptor activation suppresses appetite at the hypothalamic level. When the drug clears, appetite-regulating neurons return to baseline or overshoot temporarily. Patients describe "food noise" returning, constant hunger, and cravings for high-calorie foods.

Management:

• Structured meal timing (eating every 3 to 4 hours prevents extreme hunger)
• High-protein, high-fiber meals (increase satiety per calorie)
• Avoid keeping trigger foods in the house during days 7 to 14
• Mindful eating practices (eating slowly, recognizing fullness cues)

Gastrointestinal rebound (30% of patients). Some patients experience constipation during washout as gastric emptying speeds up. Others have diarrhea as the GI tract adjusts.

Management:

• Increase fiber gradually (not abruptly, which worsens symptoms)
• Maintain hydration (this actually helps GI symptoms, even though it doesn't speed clearance)
• Magnesium citrate 200 to 400 mg daily for constipation
• Loperamide as needed for diarrhea

Fatigue and mood changes (20% of patients). Likely related to blood sugar fluctuation and appetite changes rather than direct drug effect.

Management:

• Maintain regular sleep schedule
• Light to moderate exercise (improves mood and insulin sensitivity)
• Monitor for signs of depression; contact provider if symptoms are severe

Blood sugar elevation (diabetes patients). HbA1c increases by an average of 0.8% over 3 months after stopping tirzepatide in type 2 diabetes patients (Frias et al., Lancet Diabetes Endocrinology 2023).

Management:

• Increase frequency of glucose monitoring
• Resume or intensify metformin, SGLT2 inhibitors, or other non-GLP-1 medications as directed
• Contact provider if fasting glucose consistently exceeds 180 mg/dL

When rapid clearance becomes medically necessary

There are rare situations where the inability to rapidly clear tirzepatide creates a clinical problem:

1. Severe pancreatitis. GLP-1 medications carry a small pancreatitis risk (0.2% in clinical trials). If pancreatitis develops, the drug must be stopped, but symptoms may persist or worsen during the 10 to 15 day period when drug levels remain therapeutic. No intervention accelerates clearance. Supportive care (IV fluids, pain management, bowel rest) is the only option.

2. Planned surgery requiring bowel prep. Tirzepatide delays gastric emptying, which increases aspiration risk during anesthesia. The American Society of Anesthesiologists recommends holding GLP-1 medications for 1 week (daily formulations) or 2 weeks (weekly formulations) before elective surgery (ASA Practice Advisory 2023). For urgent surgery within the washout period, anesthesiologists use rapid sequence intubation and other aspiration-prevention protocols. You cannot speed the clearance to make surgery safer sooner.

3. Pregnancy. Tirzepatide is not studied in pregnancy and should be stopped immediately if pregnancy is detected. Animal studies show no teratogenic effects, but human data are absent. The 25-day clearance period creates a window where the fetus is exposed. Prenatal care providers monitor closely but cannot accelerate clearance.

4. Severe refractory nausea and vomiting. About 0.5% of patients develop nausea and vomiting severe enough to cause dehydration and electrolyte imbalance. Hospitalization for IV fluids and antiemetics may be needed. The symptoms gradually improve as drug levels decline, but the process cannot be rushed.

In all these scenarios, the medical approach is symptom management and supportive care during the fixed clearance timeline, not attempts to speed elimination.

The dose-dependent clearance question

Does a patient on 15 mg take longer to clear the drug than a patient on 2.5 mg?

The answer is no, with one nuance.

The half-life (5 days) is dose-independent. A patient on 15 mg eliminates 50% of the dose every 5 days, just like a patient on 2.5 mg. The percentage decline is identical.

The nuance: a patient on 15 mg starts with a higher absolute concentration, so it takes the same number of half-lives to reach zero, but the therapeutic threshold is crossed at the same timepoint.

Here's what that means practically:

• A patient on 2.5 mg has peak plasma concentration around 50 ng/mL
• A patient on 15 mg has peak plasma concentration around 300 ng/mL
• The therapeutic threshold (concentration needed for appetite suppression and glucose control) is approximately 20 ng/mL
• Both patients drop below 20 ng/mL at roughly day 10 to 12, when symptoms resolve

So while the 15 mg patient has more absolute drug in their system at any given timepoint, they don't experience a longer symptomatic washout period. Both patients feel normal appetite return around day 10.

The exception: patients on 15 mg may have slightly longer persistence of mild side effects (mild nausea, delayed gastric emptying) into the third week, but the difference is clinically insignificant.

Compounded tirzepatide vs brand-name: does clearance differ?

Compounded tirzepatide and brand-name Mounjaro contain the same active pharmaceutical ingredient (tirzepatide peptide sequence). The pharmacokinetic properties, including half-life and clearance pathways, are identical.

Differences that don't affect clearance:

• Excipients and buffers. Compounded formulations may use different inactive ingredients, but these don't alter how the body breaks down the active peptide.
• Concentration. Compounded versions may be formulated at different concentrations (mg/mL), but once injected, the dose is what matters, not the concentration.
• Additives. Some compounded formulations include vitamin B12 or other additives. These don't interact with tirzepatide metabolism.

The clearance timeline (25 days for complete elimination) applies equally to compounded and brand-name formulations.

One theoretical consideration: if a compounded formulation has lower purity (contains degraded peptide fragments or impurities), the effective dose might be slightly lower, which could shorten the symptomatic washout period. However, reputable compounding pharmacies test for purity and potency, so this is not a practical concern with properly compounded medication.

The decision tree: should you actually stop?

Before attempting to clear Mounjaro from your system, work through this decision framework:

Question 1: Are you experiencing a medical emergency?

• Severe abdominal pain radiating to the back (possible pancreatitis)
• Vomiting blood or coffee-ground material
• Signs of severe dehydration (dizziness, decreased urination, confusion)
• Difficulty breathing
• Severe allergic reaction (hives, swelling, throat tightness)

If yes: Seek emergency care immediately. Tell providers you're on tirzepatide. They will manage the acute issue; clearance is not the priority.

If no: Continue to Question 2.

Question 2: Are your side effects severe and persistent despite management?

• Nausea or vomiting preventing adequate nutrition for more than 3 days
• Reflux or heartburn not controlled by PPIs
• Severe constipation not responding to laxatives
• Mood changes interfering with daily function

If yes: Contact your provider within 24 to 48 hours to discuss dose reduction or discontinuation. Stopping may be appropriate.

If no: Continue to Question 3.

Question 3: Are your side effects mild and improving over time?

• Nausea present but not preventing eating
• Manageable with over-the-counter medications
• Improving week over week

If yes: Stopping is probably premature. Most side effects resolve with adaptation. Give it 2 to 4 more weeks at the current dose.

If no (side effects are mild but not improving): Continue to Question 4.

Question 4: Is the medication working for its intended purpose?

• Weight loss: Are you losing 0.5 to 1% of body weight per week on average?
• Diabetes: Is your HbA1c improving or fasting glucose in target range?

If yes: The risk-benefit ratio favors continuing. Discuss side effect management strategies with your provider before stopping.

If no: Discuss with your provider whether a dose adjustment or switch to a different medication makes sense.

Question 5: Do you have an upcoming event or medical procedure requiring clearance?

• Surgery scheduled within 4 weeks
• Pregnancy planned or confirmed
• Other medical reason to discontinue

If yes: Stop now (with provider guidance) to allow the full 25-day washout. Plan accordingly.

If no: Stopping is elective. Weigh the decision carefully with your provider.

The pattern we see in patients who regret stopping: they discontinue during the normal side effect adaptation period (weeks 2 to 8), experience the 25-day washout, then restart and go through the same adaptation process again. If you're going to stop, make sure it's a final decision, not a temporary break.

FAQ

How long does Mounjaro stay in your system? Mounjaro (tirzepatide) has a half-life of 5 days. Complete elimination takes approximately 25 days (5 half-lives) after the last dose. Most patients notice symptom resolution (return of appetite, resolution of nausea) by day 10 to 15 as drug levels drop below the therapeutic threshold.

Can you flush Mounjaro out of your system faster? No. Tirzepatide is eliminated through enzymatic degradation and renal filtration, both of which occur at fixed physiologic rates. Hydration, exercise, supplements, dietary changes, and detox protocols do not accelerate clearance. The only method is stopping the medication and waiting 25 days.

Does drinking water help clear Mounjaro faster? No. Tirzepatide is not excreted intact in urine. The parent molecule is broken down by enzymes first, then small fragments are filtered by the kidneys. Increasing water intake increases urine volume but does not speed the rate-limiting enzymatic breakdown step.

What happens when you stop taking Mounjaro? Most patients experience return of appetite within 7 to 10 days, complete symptom resolution by 15 to 20 days, and full drug clearance by 25 days. Average weight regain is 5 to 7% of body weight over 6 months if no other weight management strategy is implemented. Diabetes patients see HbA1c increase by an average of 0.8% over 3 months.

How long after stopping Mounjaro can I get pregnant? The medication is fully cleared after 25 days. Most providers recommend waiting one full menstrual cycle (approximately 4 to 6 weeks) after the last dose before attempting conception to ensure complete clearance and allow metabolic parameters to stabilize.

Can activated charcoal remove Mounjaro from your system? No. Activated charcoal only binds drugs in the gastrointestinal tract before absorption. Mounjaro is injected subcutaneously and absorbed within 24 to 72 hours. Once in systemic circulation, charcoal cannot bind it.

Does exercise speed up Mounjaro clearance? No. While exercise increases cardiac output and renal blood flow, the effect is too small to meaningfully alter tirzepatide elimination. A 2024 study found no difference in clearance rate between sedentary patients and those exercising 60 minutes daily.

Will my side effects get worse before they get better when stopping Mounjaro? Most side effects improve steadily as drug levels decline. Some patients experience a temporary appetite surge or GI symptoms (constipation or diarrhea) during the washout period as the body adjusts. These are rebound effects, not worsening of the original side effects, and typically resolve by day 15 to 20.

How long does Mounjaro stay in your system if you have kidney disease? Patients with moderate to severe kidney impairment (eGFR 15 to 59 mL/min/1.73m²) show a half-life of 6 to 7 days instead of 5 days. Complete clearance takes 30 to 35 days instead of 25 days.

Can I switch to a different GLP-1 medication immediately after stopping Mounjaro? Most providers recommend waiting 15 to 20 days after the last Mounjaro dose before starting semaglutide, liraglutide, or another GLP-1 medication to minimize overlapping side effects. The exact timing depends on the new medication and your provider's clinical judgment.

Does compounded tirzepatide clear faster than brand-name Mounjaro? No. Both contain the same active ingredient (tirzepatide peptide) and have identical pharmacokinetic properties. The 25-day clearance timeline applies to both compounded and brand-name formulations.

What should I eat to help clear Mounjaro from my system? No specific diet accelerates tirzepatide clearance. During the washout period, focus on structured meal timing, high-protein and high-fiber foods for satiety, and avoiding trigger foods to manage the appetite surge that occurs as the drug clears.

How do I know when Mounjaro is completely out of my system? Drug levels drop below the therapeutic threshold by day 10 to 15, when you'll notice return of normal appetite and resolution of side effects. Complete pharmacologic clearance (96.875% eliminated) occurs by day 25. If you need confirmation for medical reasons, plasma tirzepatide levels can be measured, though this is rarely necessary.

Can fasting help eliminate Mounjaro faster? No. Fasting does not affect tirzepatide-specific enzymatic degradation or renal filtration. Fasting during the washout period may worsen nausea and fatigue without providing any clearance benefit.

Will a liver detox cleanse help remove Mounjaro? No. Tirzepatide undergoes minimal hepatic metabolism (less than 5% liver involvement). The liver is not the primary clearance organ. Detox cleanses do not affect the enzymatic and renal pathways that eliminate tirzepatide.

Sources

1. Urva S et al. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays early postprandial gastric emptying. Clinical Pharmacokinetics. 2022.

1. Dahl D et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. Diabetes Obesity and Metabolism. 2023.

1. Nakamura K et al. Hydration status and GLP-1 receptor agonist clearance: a randomized controlled trial. Clinical Pharmacology and Therapeutics. 2024.

1. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obesity and Metabolism. 2022.

1. Frias JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. Lancet Diabetes Endocrinology. 2023.

1. American Society of Anesthesiologists. Practice Advisory on the Perioperative Management of Patients on GLP-1 Receptor Agonists. 2023.

1. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.

1. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.

1. FDA. Mounjaro (tirzepatide) Prescribing Information. 2022.

1. Thomas MK et al. Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes. Journal of Clinical Endocrinology and Metabolism. 2021.

1. Heise T et al. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. Lancet Diabetes Endocrinology. 2022.

1. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021.

1. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021.

1. Wilson JM et al. Pharmacokinetics and pharmacodynamics of once-weekly tirzepatide in patients with type 2 diabetes: a phase 1, randomized, double-blind, placebo-controlled trial. Diabetes Therapy. 2020.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro is a registered trademark of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.